News and Events

For all media enquiries, please contact Breakthrough Media Centre:

Press office
Email: press@breakthrough.org.uk
Tel: 020 7025 2432 / 2460
Fax: 020 7025 2401
Out of hours: 07778 682001

  • Domainex Collaboration on Novel Drug Targets

    20 Mar 2009
    Domainex today announced a collaboration on new exciting drug discovery programmes with the Breakthrough Breast Cancer Research Centre and The Institute of Cancer Research (ICR) to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon.
  • Antisoma collaboration on novel approach to cancer treatment

    07 Oct 2008
    Cancer drug developer Antisoma (LSE: ASM; USOTC: ATSMY), The Institute of Cancer Research (The Institute) and Cancer Research Technology (CRT) today announced a collaboration and licensing agreement under which Antisoma has acquired rights to develop and commercialise novel anti-cancer compounds called PPM1D (protein phosphatase magnesium-dependent 1 ) inhibitors. Work carried out at the Breakthrough Breast Cancer Research Centre and at the Cancer Research UK Centre for Cancer Therapeutics, both of which are at The Institute, showed that these compounds inhibit PPM1D and selectively kill cells that over-express this phosphatase.
  • CDK10 is an Important Determinant of Resistance to EndocrineTherapy

    05 Feb 2008
    Scientists at the Breakthrough Breast Cancer Research Centre have identified how some breast cancers may become resistant to hormone treatments like tamoxifen. The study, published in the February issue of Cancer Cell, shows for the first time that a protein called CDK10 is able to control the development of tamoxifen resistance in hormone sensitive breast cancer, and has potentially important implications in the treatment of women with this form of the disease.
  • Debate at NCRI conference

    25 Sep 2007
    Breakthrough Breast Cancer and Breast Cancer Campaign will be holding a joint debate at the NCRI conference in Birmingham on Sunday 30th September. The debate is titled 'Breast cancer prevention in 2025: targeted chemoprevention or lifestyle change'.
  • Patients begin enrolling in studies to determine if women with BRCA 1 & 2 positive cancer may receive greater benefit from new treatment

    19 Jun 2007
    AstraZeneca Collaborates with Myriad Genetics on Phase 2 Trials. AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 positive breast and ovarian cancer. Myriad Genetics, Inc. (Nasdaq: MYGN, www.myriad.com), is providing the molecular diagnostic testing (BRACAnalysis™) for these trials. Dr Andrew Tutt, clinician scientist at the Breakthrough Breast Cancer Research Centre and breast oncologist at Guy’s Hospital, London is Lead Investigator for the trials.
  • BRCA1 dysfunction in sporadic basal-like breast cancer

    29 Mar 2007
    Breakthrough scientists have identified a high prevalence of BRCA1 dysfunction in basal-like breast cancers. This finding could be exploited to develop novel targeted therapies for this particular type of breast cancer.